VLP Based Coronavirus Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 26022
Special Issue Editors
Interests: virus-like particles; vaccines; infectious diseases; immunology; antibody; allergy; cancer immunotherapy and immunology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The COVID-19 pandemic has paralyzed the world, however with the advent of registered vaccines, a silver lining is on the horizon. These novel vaccines are, however, based on novel techniques, which do not yet have the full experience package of classical vaccines. On the other hand, the use of virus-like particles (VLPs) is one such classical vaccine approach. In this Special Issue of Vaccines, we would like to highlight the various efforts made and techniques used in the development of virus-like particle (VLP)-based COVID-19 vaccines. We would like to cover all aspects of vaccine development, from vaccine design to vaccine production, as well as preclinical and clinical efficacy. This Special Issue will highlight the power of the classical VLP-based approach und underline the importance that such avenues are still pursued to back up the vaccines currently undergoing registration.
Prof. Dr. Martin Bachmann
Dr. Mona Mohsen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- virus-like particles (VLPs)
- vaccine
- vaccine design
- vaccine development
- vaccine production
- pre-clinical studies
- clinical trials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.